TY - JOUR T1 - A model-based approach to improve intranasal sprays for respiratory viral infections JF - medRxiv DO - 10.1101/2022.01.26.22269854 SP - 2022.01.26.22269854 AU - Saikat Basu AU - Mohammad Mehedi Hasan Akash AU - Yueying Lao AU - Pallavi A Balivada AU - Phoebe Ato AU - Nogaye K Ka AU - Austin Mituniewicz AU - Zachary Silfen AU - Julie Suman AU - Arijit Chakravarty AU - Diane Joseph-McCarthy Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/28/2022.01.26.22269854.abstract N2 - Drug delivery for viral respiratory infections, such as SARS-CoV-2, can be enhanced significantly by targeting the nasopharynx, which is the dominant initial infection site in the upper airway, for example by nasal sprays. However, under the standard recommended spray usage protocol (“Current Use”, or CU), the nozzle enters the nose almost vertically, resulting in sub-optimal deposition of drug droplets at the nasopharynx. Using computational fluid dynamics simulations in two anatomic nasal geometries, along with experimental validation of the generic findings in a different third subject, we have identified a new “Improved Use” (or, IU) spray protocol. It entails pointing the spray bottle at a shallower angle (almost horizontally), aiming slightly toward the cheeks. We have simulated the performance of this protocol for conically injected spray droplet sizes of 1 – 24 μm, at two breathing rates: 15 and 30 L/min. The lower flowrate corresponds to resting breathing and follows a viscous-laminar model; the higher rate, standing in for moderate breathing conditions, is turbulent and is tracked via Large Eddy Simulation. The results show that (a) droplets sized between ∼ 6 – 14 μm are most efficient at direct landing over the nasopharyngeal viral infection hot-spot; and (b) targeted drug delivery via IU outperforms CU by approximately 2 orders-of-magnitude, under the two tested inhalation conditions. Also quite importantly, the improved delivery strategy, facilitated by the IU protocol, is found to be robust to small perturbations in spray direction, underlining the practical utility of this simple change in nasal spray administration protocol.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is based on work partially supported by the National Science Foundation (NSF) RAPID Grant 2028069 for COVID-19 research, with SB as the Co-Principal Investigator. Any opinions, findings, and conclusions or recommendations expressed here are, however, those of the authors and do not necessarily reflect views of the NSF.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of the archived and anonymized medical records was approved with exempt status by the Institutional Review Board (IRB) of the University of North Carolina (UNC) at Chapel Hill, with the requirement for informed consent being waived in view of retrospective use for computational research.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding author. ER -